Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given signed consent before any study-related activities begin.
- People for whom the treating doctor and the patient (or their legal representative) have already decided — independently from this study — to start treatment with the commercially available medication Awiqli.
- People of any age, male or female.
- People who have been diagnosed with diabetes mellitus, with no restrictions on the type of diabetes or previous diabetes treatments.
Who may not be able to join:
- People who have previously taken part in this same study by giving informed consent.
- People who have taken part in another clinical trial involving an experimental drug within the 30 days before joining this study.
- People who, due to mental capacity, unwillingness, or language barriers, are unable to adequately understand or cooperate with the study.
- People for whom this medication is listed as not suitable (contraindicated) according to the official Japanese prescribing information.
- People who are currently experiencing symptoms of low blood sugar (hypoglycaemia).
- People who have had an allergic reaction to any ingredient in this medication in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Adverse Reactions (ARs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.